Duopharma Biotech Berhad Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Leonard bin Abdul Shatar

Algemeen directeur

RM 2.5k

Totale compensatie

Percentage CEO-salaris	47.8%
Dienstverband CEO	16.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	6.7yrs

Recente managementupdates

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

Analyse CEO-vergoeding

Hoe is Leonard bin Abdul Shatar's beloning veranderd ten opzichte van Duopharma Biotech Berhad's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	RM 49m
Mar 31 2024	n/a	n/a	RM 45m
Dec 31 2023	RM 3k	RM 1k	RM 53m
Sep 30 2023	n/a	n/a	RM 61m
Jun 30 2023	n/a	n/a	RM 69m
Mar 31 2023	n/a	n/a	RM 72m
Dec 31 2022	RM 2m	RM 1m	RM 70m
Sep 30 2022	n/a	n/a	RM 69m
Jun 30 2022	n/a	n/a	RM 69m
Mar 31 2022	n/a	n/a	RM 68m
Dec 31 2021	RM 2m	RM 1m	RM 66m
Sep 30 2021	n/a	n/a	RM 66m
Jun 30 2021	n/a	n/a	RM 63m
Mar 31 2021	n/a	n/a	RM 63m
Dec 31 2020	RM 2m	RM 924k	RM 59m
Sep 30 2020	n/a	n/a	RM 54m
Jun 30 2020	n/a	n/a	RM 55m
Mar 31 2020	n/a	n/a	RM 54m
Dec 31 2019	RM 2m	RM 882k	RM 55m
Sep 30 2019	n/a	n/a	RM 58m
Jun 30 2019	n/a	n/a	RM 55m
Mar 31 2019	n/a	n/a	RM 51m
Dec 31 2018	RM 1m	RM 876k	RM 48m

Compensatie versus markt: De totale vergoeding ($USD 580.36 ) Leonard } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de MY markt ($USD 152.34K ).

Compensatie versus inkomsten: De vergoeding van Leonard is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Leonard bin Abdul Shatar (59 yo)

16.8yrs

Tenure

RM 2,533

Compensatie

Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ariff bin Abdul Shatar	Group MD & Executive Director	16.8yrs	RM 2.53k	geen gegevens
Wu Chek	Chief Financial Officer	12.3yrs	geen gegevens	0.000010% MYR 123.1
Ibrahim Salleh	Chief Legal Officer & Group Company Secretary	6.9yrs	geen gegevens	geen gegevens
Sabrina Haron	Chief Compliance Officer	1.3yrs	geen gegevens	geen gegevens
Krisnakumara Reddi	Chief Manufacturing & Sustainability Officer	2.1yrs	geen gegevens	0.00030% MYR 3.7k
Wan Ahmad Bin Wan Mohd. Salleh	Group Head of Risk Management & Integrity	1.8yrs	geen gegevens	geen gegevens
Priya Asokan	Chief Innovation Officer	less than a year	geen gegevens	geen gegevens
Shamsul Bin A. Iahad	Chief Executive Officer of Duopharma Consumer Healthcare Sdn. Bhd.	4.8yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ariff bin Abdul Shatar	Group MD & Executive Director	6.9yrs	RM 2.53k	geen gegevens
Nik Binti Nik Mohamed Shihabuddin	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Razalee Bin Amin	Independent Non-Executive Director	8.4yrs	RM 130.80k	geen gegevens
Mohd Bin Mohd Yunus	Non Independent Non Executive Director	6.7yrs	RM 146.40k	0.0026% MYR 32.4k
Nik Bin Nik Hassan	Independent Non-Executive Director	6.9yrs	RM 143.80k	geen gegevens
Zaki Bin Mohamad Zaher	Independent Non-Executive Director	5.2yrs	RM 135.40k	geen gegevens
Zaiton Binti Jamaluddin	Independent Non Executive Director	8.2yrs	RM 143.80k	geen gegevens
Eisah Binti Rahman	Senior Independent Non-Executive Director	8yrs	RM 141.40k	geen gegevens
Kartini Binti Abdul Manaf	Non-Independent & Non-Executive Chairman	1.4yrs	RM 76.70k	geen gegevens
Muhammad Bin Ismail	Non Independent & Non Executive Alternate Director	1.3yrs	geen gegevens	geen gegevens
Mohd Bin Mohd Arshad	Non-Independent & Non-Executive Director	less than a year	geen gegevens	geen gegevens

6.7yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).

Duopharma Biotech Berhad Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Recent updates

Second quarter 2024 earnings released: EPS: RM0.017 (vs RM0.013 in 2Q 2023)

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week

New 90-day low: RM3.03

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Revenue behind estimates

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Price target raised to RM2.45

Government of Malaysia, Biocon Sdn. Bhd. and Duopharma Biotech Berhad Extends the Contract Period Under the Agreement One Year Effective from 2 December 2020 Until 1 December 2021

Duopharma Biotech Berhad Announces Temporary Closure of Registered Office

First half earnings released

New 90-day high - RM3.29